When you believe in your tools, nothing can stop you.
IDT will be participating in ESHG 2021 virtually this year. Learn about our solutions for life sciences and medical research, serving the academic, clinical, biotechnology, pharmaceutical development, and agricultural research communities. IDT’s NGS products are a critical part of oncology research, inherited and infectious disease research, biomarker development, diagnostics, and early screening.
Visit IDT at the virtual booth and talk to an expert!
Facing a tough challenge in the lab? Have questions about our products? We’d love to help. Connect with an IDT expert one on one during the virtual exhibit.
Corporate satellite presentation
IDT will be hosting a corporate satellite again this year. Join us for a 30-minute on-demand presentation.
- Design and optimization of a new NGS targeted sequencing panel for detecting somatic mutations in hematological malignancies
Dr. Ushati Das Chakravarty, Next Generation Sequencing Product Manager, IDT
Dr. Wendy Parker, Senior Medical Scientist. SA Pathology
Dr. Anna Brown, Head of Molecular Oncology, SA Pathology
Next generation sequencing (NGS) can be used to detect somatic mutations in hematological malignancies for diagnosis, prognostication, and therapy selection. Our pathology centre has offered NATA-accredited NGS for molecular diagnostics for myeloid malignancies since 2019, utilizing a custom Roche SeqCap EZ capture panel targeting the full coding region of 41 genes (0.1 Mb). The Myeloid panel was designed for primary myeloproliferative neoplasms (MPN), myelodysplastic syndromes, acute myeloid leukemia, and therapy-related myeloid neoplasms.
We recently redesigned our panel to also test somatic mutation hotspot regions important for lymphoid malignancies and triple negative MPN (TN-MPN). The new custom IDT xGen™ Custom Hyb Panel covers 21 full genes, selected exons of a further 25 genes, and common SNPs on chromosomes 9 and 17 for simultaneous LOH analysis (0.07 Mb). IDT provided benchmarking results before we started testing, bolstering our confidence. The new Haem Panel has enhanced coverage uniformity and the smaller target region has allowed for batch size increases by 50%, while maintaining similar mean coverage (>1000X) using a MiSeq instrument. Capture of the additional genes allows us to increase our scope of testing to more hematological cancer patients, which could contribute to improved outcomes for cancer patients in South Australia.
Explore some of our NGS solutions
xGen Prism DNA Library Prep Kit
xGen Exome Research Panel v2
NGS Discovery Pools
xGen Lockdown Probe Pools
xGen Lockdown Panels
xGen Blocking Oligos
Custom NGS Adapters